Roche pays $7.1B to Roivant for rights to Telavant’s IBD candidate

Roche on Monday announced a definitive agreement to acquire Roivant’s subsidiary Televant Holdings, granting the Swiss drugmaker ownership of the investigational anti-TL1A antibody RVT-3101 which is being developed for inflammatory bowel diseases including ulcerative colitis and Crohn’s disease.